Institute of Reproductive Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Assist Reprod Genet. 2023 Jul;40(7):1533-1558. doi: 10.1007/s10815-023-02823-x. Epub 2023 May 30.
Recurrent pregnancy loss (RPL) is affecting 1-4% of women who conceive approximately, and no cause could be found in more than 50% of women suffering from RPL. Inherited thrombophilias have got increasing attention in women with unexplained RPL, so we aim to explore the relationship among these most common thrombophilic polymorphisms and RPL through a literature review and meta-analysis.
Observational studies from PubMed, Embase, Cochrane, and Web of Science from 1997 to 7 April 2022 were searched. For each genetic variant, a fixed or random-effect model was used according to the heterogeneity test to calculate pooled ORs and 95% CIs for both dominant and recessive genetic models. Egger's line regression test was used to assess publication bias. The quality of the included articles was assessed by the Newcastle Ottawa scale.
A total of 124 articles comprising 17,278 RPL patients and 16,021 controls were included. Results showed that hyperhomocysteinemia (MTHFR) C677T (dominant model: OR, 1.43; 95% CI, 1.25-1.64; recessive model: OR, 1.60; 95% CI, 1.36-1.87), MTHFR A1298C (dominant model: OR, 1.66; 95% CI, 1.26-2.18; recessive model: OR, 1.79; 95% CI, 1.42-2.26), PAI-1 4G/5G (dominant model: OR, 1.67; 95% CI, 1.36-2.06; recessive model: OR, 1.80; 95% CI, 1.39-2.32), angiotensin-converting enzyme I/D (OR, 1.23; 95% CI, 1.00-1.53), Factor XIII V34L (OR, 1.38; 95% CI, 1.02-1.87), and β-fibrinogen-455G/A (OR, 1.60; 95% CI, 1.02-2.51) were significantly associated with RPL.
This study provides potentially useful clinical markers to evaluate the risk of RPL or to help unexplained RPL patients identify possible causes, which may allow for targeted treatment.
复发性妊娠丢失(RPL)影响了约 1-4%的妊娠女性,而在 50%以上的 RPL 患者中,仍无法找到病因。遗传性血栓形成倾向在不明原因的 RPL 女性中受到越来越多的关注,因此我们旨在通过文献回顾和荟萃分析来探讨这些最常见的血栓形成倾向基因多态性与 RPL 之间的关系。
检索了 1997 年至 2022 年 4 月 7 日期间来自 PubMed、Embase、Cochrane 和 Web of Science 的观察性研究。对于每种遗传变异,根据异质性检验,使用固定或随机效应模型来计算优势和隐性遗传模型的合并 OR 和 95%CI。采用 Egger 线性回归检验评估发表偏倚。使用纽卡斯尔-渥太华量表评估纳入文章的质量。
共纳入了 124 篇文章,包含 17278 名 RPL 患者和 16021 名对照。结果显示,高同型半胱氨酸血症(MTHFR)C677T(优势模型:OR,1.43;95%CI,1.25-1.64;隐性模型:OR,1.60;95%CI,1.36-1.87)、MTHFR A1298C(优势模型:OR,1.66;95%CI,1.26-2.18;隐性模型:OR,1.79;95%CI,1.42-2.26)、PAI-1 4G/5G(优势模型:OR,1.67;95%CI,1.36-2.06;隐性模型:OR,1.80;95%CI,1.39-2.32)、血管紧张素转换酶 I/D(OR,1.23;95%CI,1.00-1.53)、因子 XIII V34L(OR,1.38;95%CI,1.02-1.87)和β-纤维蛋白原-455G/A(OR,1.60;95%CI,1.02-2.51)与 RPL 显著相关。
本研究提供了潜在有用的临床标志物来评估 RPL 的风险或帮助不明原因的 RPL 患者确定可能的病因,这可能允许进行针对性治疗。